Last updated: 18 June 2024 at 4:42pm EST

George Bickerstaff Net Worth




The estimated Net Worth of George Bickerstaff is at least $5.72 Milione dollars as of 14 May 2024. Mr. Bickerstaff owns over 5,255 units of Innoviva Inc stock worth over $2,036,534 and over the last 10 years he sold INVA stock worth over $3,355,950. In addition, he makes $324,994 as Independent Director at Innoviva Inc.

Mr. Bickerstaff INVA stock SEC Form 4 insiders trading

George has made over 15 trades of the Innoviva Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 5,255 units of INVA stock worth $52,550 on 14 May 2024.

The largest trade he's ever made was selling 25,000 units of Innoviva Inc stock on 28 February 2022 worth over $977,750. On average, George trades about 3,045 units every 28 days since 2014. As of 14 May 2024 he still owns at least 104,976 units of Innoviva Inc stock.

You can see the complete history of Mr. Bickerstaff stock trades at the bottom of the page.





George Bickerstaff biography

George W. Bickerstaff III serves as Independent Director of the Company. He is currently a member of the Audit Committee of the Board of Directors (the "Audit Committee") and the Compensation Committee of the Board of Directors (the "Compensation Committee"). He currently serves as a Managing Director of M.M. Dillon & Co., LLC, an investment banking firm. Prior to joining M.M. Dillon & Co., LLC, Mr. Bickerstaff held various positions with Novartis International AG, a global leader in pharmaceuticals and consumer health, including Chief Financial Officer of Novartis Pharma AG. Prior to joining Novartis, Mr. Bickerstaff was the Chief Financial Officer of IMS Health, Division of Dun & Bradstreet. Mr. Bickerstaff currently serves on the board of directors of CareDx, Inc. and Cardax, Inc. Mr. Bickerstaff previously served on the board of directors of Axovant Sciences Ltd, Inovio Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. until it was acquired by Takeda Pharmaceutical Company Limited in February 2017. Mr. Bickerstaff has demonstrated leadership in his field, his understanding of our industry and his senior management experience contributed to our conclusion that he should serve as a director.

What is the salary of George Bickerstaff?

As the Independent Director of Innoviva Inc, the total compensation of George Bickerstaff at Innoviva Inc is $324,994. There are 3 executives at Innoviva Inc getting paid more, with Marianne Zhen having the highest compensation of $551,918.



How old is George Bickerstaff?

George Bickerstaff is 64, he's been the Independent Director of Innoviva Inc since 2017. There are 1 older and 6 younger executives at Innoviva Inc. The oldest executive at Innoviva Inc is Jules Haimovitz, 69, who is the Independent Director.

What's George Bickerstaff's mailing address?

George's mailing address filed with the SEC is C/O CAREDX, INC., 8000 MARINA BOULEVARD, BRISBANE, CA, 94005.

Insiders trading at Innoviva Inc

Over the last 9 years, insiders at Innoviva Inc have traded over $394,127,811 worth of Innoviva Inc stock and bought 682,000 units worth $8,768,520 . The most active insiders traders include Plc Gsk, Alexander J Sarissa Capital... e Patrick G Lepore. On average, Innoviva Inc executives and independent directors trade stock every 78 days with the average trade being worth of $18,199,955. The most recent stock trade was executed by Marianne Zhen on 15 November 2023, trading 10,994 units of INVA stock currently worth $153,806.



What does Innoviva Inc do?

innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.



What does Innoviva Inc's logo look like?

Innoviva Inc logo

Complete history of Mr. Bickerstaff stock trades at Caredx Inc, Innoviva Inc, Inovio Pharmaceuticals Inc e Axovant Gene Therapies

Data
#
Ditta
Persona
Trans.
Transazione
Azioni Prezzo per azione Prezzo totale Azioni dopo Fonte
14 May 2024 George Bickerstaff
Opzione 5,255 $10.00 $52,550
14 May 2024
104,976
11 Aug 2023 George Bickerstaff
Opzione 19,453 $5.09 $99,016
11 Aug 2023
99,721
23 Nov 2022 George Bickerstaff
Opzione 15,000 $1.22 $18,300
23 Nov 2022
60,101
28 Feb 2022 George Bickerstaff
Vendita 25,000 $39.11 $977,750
28 Feb 2022
37,736
21 May 2021 George Bickerstaff
Vendita 10,000 $75.34 $753,400
21 May 2021
60,938
12 May 2021 George Bickerstaff
Vendita 10,000 $63.07 $630,700
12 May 2021
70,938
14 Dec 2020 George Bickerstaff
Vendita 10,000 $71.76 $717,600
14 Dec 2020
80,487
13 May 2020 George Bickerstaff
Vendita 10,000 $27.65 $276,500
13 May 2020
85,657
21 May 2021 George Bickerstaff
Direttore
Acquistare 20,000 $13.21 $264,200
21 May 2021
124,560
27 Feb 2019 George Bickerstaff
Direttore
Acquistare 15,000 $15.90 $238,500
27 Feb 2019
53,762
21 Feb 2019 George Bickerstaff
Direttore
Acquistare 10,000 $14.90 $149,000
21 Feb 2019
38,762


Innoviva Inc executives and stock owners

Innoviva Inc executives and other stock owners filed with the SEC include: